TrianglePUBLICATIONS · 35007127
Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 2022 Mar 20
- First author
- O'Brien MM
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- O'Brien MM
- type
- Author
- name
- Ji L
- type
- Author
- name
- Shah NN
- type
- Author
- name
- Rheingold SR
- type
- Author
- name
- Bhojwani D
- type
- Author
- name
- Yuan CM
- type
- Author
- name
- Xu X
- type
- Author
- name
- Yi JS
- type
- Author
- name
- Harris AC
- type
- Author
- name
- Brown PA
- type
- Author
- name
- Borowitz MJ
- type
- Author
- name
- Militano O
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- O'Brien MM
- type
- Author
- name
- Ji L
- type
- Author
- name
- Shah NN
- type
- Author
- name
- Rheingold SR
- type
- Author
- name
- Bhojwani D
- type
- Author
- name
- Yuan CM
- type
- Author
- name
- Xu X
- type
- Author
- name
- Yi JS
- type
- Author
- name
- Harris AC
- type
- Author
- name
- Brown PA
- type
- Author
- name
- Borowitz MJ
- type
- Author
- name
- Militano O
- type
- Author
- bibliography ids
- nci-bib-2a9d943562ac22e9ee3bd980
- book metadata
- content sha256
- 0777b3aacb898c32e2ab0648cd1c8d2d9ec229ad4312270fbaa21e7de26a54ae
- document type
- citation
- dois
- 10.1200/JCO.21.01693
- electronic publication date
- display
- 2022 Jan 10
- precision
- day
- year
- 2022
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:35007127
- immutable id
- pubmed:35007127@0777b3aacb898c32e2ab0648cd1c8d2d9ec229ad4312270fbaa21e7de26a54ae
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- 1527-7755
- issn print
- 0732-183X
- issue
- 9
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 956-967
- volume
- 40
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 35007127
- provenance
- batch id
- 3f4d1914d2afe41e9e70
- provider
- NCBI PubMed ESummary
- record sha256
- 54af02bdcea1f58dcb58f9a452115f0fc89a1c6daa420612badbf7aa1c3958e3
- response sha256
- 0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
- retrieved at
- 2026-09-09T23:48:06.522634+00:00
- publication date
- display
- 2022 Mar 20
- precision
- day
- year
- 2022
- publication types
- Clinical Trial Protocol
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621.
Preserved source evidence · Not medical advice